We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
Read MoreHide Full Article
Aeglea BioTherapeutics submitted a marketing authorization application (“MAA”) to the European Medicines Agency (EMA), seeking approval for its lead candidate, pegzilarginase, for treating patients with Arginase 1 Deficiency (AGR1-D). The MAA has been validated by the EMA.
ARGN1-D is a rare progressive disease characterized by high levels of the amino acid arginine in the body, that presents in early childhood. The disease is characterized by developmental delay, seizures, intellectual disability as well as early mortality.
Pegzilarginase is a recombinant human arginase 1, engineered to enzymatically degrade arginine in the human body to normalize arginine levels in patients with ARG1-D.
The MAA for pegzilarginase was submitted by Aeglea’s commercialization partner in Europe and the Middle East, Immedica Pharma AB.
Additionally, AGLE has already submitted a biologics license application (“BLA”) to the FDA in April, for use of pegzilarginase in the treatment of ARG1-D in the United States.
Shares of Aeglea witnessed a massive surge of 80% during market hours on Aug 19, post the announcement of the news. However, the stock has declined 89.8% in the year-to-date period, compared to the industry’s decline of 20%.
Image Source: Zacks Investment Research
Results from these two studies have exhibited that pegzilarginase can rapidly and sustainably reduce arginine levels in the body, showing improvements in measures of mobility among patients.
Pegzilarginase has already received Orphan Drug Designation from the EMA. It has also received multiple regulatory designations, including Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy and Fast Track designations from the FDA.
Potential approval of pegzilarginase will provide Aeglea with its first marketed drug and the patients with a drug option.
Inozyme’s loss per share estimates for 2022 have narrowed from $2.08 to $1.84 in the past 30 days. The same for 2023 has narrowed from $1.95 to $1.82 in the same time frame.
Earnings of Inozyme missed estimates in three of the trailing four quarters and beat the same on the remaining one occasion. The average earnings surprise for INZY is 6.65%.
Rhythm’s loss per share estimates for 2022 widened from $3.74 to $3.82 in the past 30 days. The same for 2023 has narrowed from $3.40 to $3.08 in the same time frame.
Earnings of Rhythm missed estimates in two of the trailing four quarters and beat the same on the remaining two occasions. The average earnings surprise for RYTM is 2.97%.
Pliant’s loss per share estimates for 2022 have improved from $3.28 to $3.01 in the past 30 days. The same for 2023 has narrowed from $3.68 to $3.29 in the same time frame.
Earnings of Pliant beat estimates in two of the trailing four quarters, were in line in one quarter and missed the same on the remaining occasion. The average earnings surprise for PLRX is 0.90%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
Aeglea BioTherapeutics submitted a marketing authorization application (“MAA”) to the European Medicines Agency (EMA), seeking approval for its lead candidate, pegzilarginase, for treating patients with Arginase 1 Deficiency (AGR1-D). The MAA has been validated by the EMA.
ARGN1-D is a rare progressive disease characterized by high levels of the amino acid arginine in the body, that presents in early childhood. The disease is characterized by developmental delay, seizures, intellectual disability as well as early mortality.
Pegzilarginase is a recombinant human arginase 1, engineered to enzymatically degrade arginine in the human body to normalize arginine levels in patients with ARG1-D.
The MAA for pegzilarginase was submitted by Aeglea’s commercialization partner in Europe and the Middle East, Immedica Pharma AB.
Additionally, AGLE has already submitted a biologics license application (“BLA”) to the FDA in April, for use of pegzilarginase in the treatment of ARG1-D in the United States.
Shares of Aeglea witnessed a massive surge of 80% during market hours on Aug 19, post the announcement of the news. However, the stock has declined 89.8% in the year-to-date period, compared to the industry’s decline of 20%.
Image Source: Zacks Investment Research
Results from these two studies have exhibited that pegzilarginase can rapidly and sustainably reduce arginine levels in the body, showing improvements in measures of mobility among patients.
Pegzilarginase has already received Orphan Drug Designation from the EMA. It has also received multiple regulatory designations, including Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy and Fast Track designations from the FDA.
Potential approval of pegzilarginase will provide Aeglea with its first marketed drug and the patients with a drug option.
Aeglea BioTherapeutics, Inc. Price
Aeglea BioTherapeutics, Inc. price | Aeglea BioTherapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Currently, Aeglea has a Zacks Rank #3 (Hold).
Some better stocks in the same sector are Inozyme Pharma (INZY - Free Report) , Rhythm Pharmaceuticals (RYTM - Free Report) and Pliant Therapeutics (PLRX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Inozyme’s loss per share estimates for 2022 have narrowed from $2.08 to $1.84 in the past 30 days. The same for 2023 has narrowed from $1.95 to $1.82 in the same time frame.
Earnings of Inozyme missed estimates in three of the trailing four quarters and beat the same on the remaining one occasion. The average earnings surprise for INZY is 6.65%.
Rhythm’s loss per share estimates for 2022 widened from $3.74 to $3.82 in the past 30 days. The same for 2023 has narrowed from $3.40 to $3.08 in the same time frame.
Earnings of Rhythm missed estimates in two of the trailing four quarters and beat the same on the remaining two occasions. The average earnings surprise for RYTM is 2.97%.
Pliant’s loss per share estimates for 2022 have improved from $3.28 to $3.01 in the past 30 days. The same for 2023 has narrowed from $3.68 to $3.29 in the same time frame.
Earnings of Pliant beat estimates in two of the trailing four quarters, were in line in one quarter and missed the same on the remaining occasion. The average earnings surprise for PLRX is 0.90%.